07:00 , Jun 22, 2015 |  BC Week In Review  |  Company News

Epirus, Chemo Group deal

Epirus granted Chemo’s mAbxience subsidiary rights to commercialize BOW015 in Argentina, Chile, Ecuador, Paraguay, Uruguay and Venezuela. BOW015 is a biosimilar version of autoimmune drug Remicade infliximab from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.)...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Clinical News

Infimab infliximab regulatory update

The Drug Controller General of India (DCGI) approved manufacturing and marketing of autoimmune therapy Infimab infliximab from Epirus. Infimab is India's first approved biosimilar of Remicade from Johnson & Johnson (NYSE:JNJ, New Brunswick) and Merck...
07:00 , Apr 21, 2014 |  BioCentury  |  Finance

European beachhead

European beachhead Epirus Biopharmaceuticals Inc. hopes its $36 million series B round and reverse merger with Zalicus Inc. (NASDAQ:ZLCS) will enable the biosimilars company to crack the European market. The combined public company will retain...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

Epirus, Ranbaxy deal

Epirus granted Ranbaxy rights to commercialize BOW015 in India and undisclosed markets in Southeast Asia and North Africa. BOW015 is a biosimilar version of autoimmune drug Remicade infliximab from Johnson & Johnson (NYSE:JNJ, New Brunswick,...
02:08 , Jan 9, 2014 |  BC Extra  |  Company News

Epirus grants Ranbaxy biosimilar marketing rights

Epirus Biopharmaceuticals Inc. (Boston, Mass.) granted Ranbaxy Laboratories Ltd. (NSE:RANBAXY; BSE:500359) rights to commercialize BOW015 in India and undisclosed markets in Southeast Asia and North Africa. BOW015 is a biosimilar version of autoimmune drug Remicade...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Company News

Biolab Sanus Farmaceutica, Epirus, Eurofarma Laboratorios deal

Epirus partnered with Orygen Biotecnologia Ltda. - a JV between Eurofarma and Biolab Sanus - to develop and commercialize biosimilars in Brazil. The deal includes Epirus' BOW015 , a biosimilar of Remicade infliximab, as well...
00:48 , Oct 23, 2013 |  BC Extra  |  Company News

Epirus, Orygen in Brazilian biosimilars deal

Epirus Biopharmaceuticals Inc. (Boston, Mass.) partnered with the JV Orygen Biotecnologia Ltda. to develop and commercialize biosimilars in Brazil. The deal includes Epirus' BOW015 , a biosimilar of Remicade infliximab, as well as two additional...